Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Blödarsjuka med HIV. Långsammare infektionsförlopp hos yngre och vid större förbrukning av faktorkoncentrat

Astermark, Jan LU ; Berntorp, Erik LU ; Stigendal, Lennart and Johnsson, Hans (1998) In Läkartidningen 95(1). p.48-50
Abstract
HIV disease progression and the effect of replacement therapy with clotting factor concentrates (CFCs) were studied in 100 Swedish haemophiliacs, mean age at seroconversion 29 years (range, 4-72). On average 16 years after seroconversion, 67 per cent of the patients had CD4+ cell counts of < 200 x 10(6)/l, 50 per cent had developed AIDS, and 58 per cent had died. HIV disease progression was significantly slower in those aged less than 28 (median age) at seroconversion (P = 0.004). Moreover, mortality was inversely correlated to total annual CFC consumption after adjustment for age and HIV-related therapy, i.e., Pneumocystis carinii prophylaxis and antiretroviral drugs (P = 0.014), but unrelated to the purity of the CFCs used. After... (More)
HIV disease progression and the effect of replacement therapy with clotting factor concentrates (CFCs) were studied in 100 Swedish haemophiliacs, mean age at seroconversion 29 years (range, 4-72). On average 16 years after seroconversion, 67 per cent of the patients had CD4+ cell counts of < 200 x 10(6)/l, 50 per cent had developed AIDS, and 58 per cent had died. HIV disease progression was significantly slower in those aged less than 28 (median age) at seroconversion (P = 0.004). Moreover, mortality was inversely correlated to total annual CFC consumption after adjustment for age and HIV-related therapy, i.e., Pneumocystis carinii prophylaxis and antiretroviral drugs (P = 0.014), but unrelated to the purity of the CFCs used. After adjustment for age, annual CFC consumption and HIV-therapy, prophylactic replacement therapy was not associated with significantly better survival than on-demand treatment. It is concluded that in HIV-positive haemophiliacs replacement therapy may have a beneficial effect on the immune system, and that CFC purity and the regimen (prophylaxis vs on-demand) would seem to be factors of minor importance. (Less)
Please use this url to cite or link to this publication:
author
; ; and
organization
alternative title
Hemophiliacs with HIV. Slower progression of the infection among younger patients and at higher dosages of factor concentrates
publishing date
type
Contribution to journal
publication status
published
subject
keywords
HIV-positivitet, Blödarsjuka, Hemofili B, Blodburen smitta, Faktor VIII, Faktor IX, Åldersfaktorer, Aids, AIDS-relaterade opportunistiska infektioner
in
Läkartidningen
volume
95
issue
1
pages
48 - 50
publisher
Swedish Medical Association
external identifiers
  • pmid:9458646
  • scopus:0032491704
ISSN
0023-7205
language
Swedish
LU publication?
yes
additional info
The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Clinical Coagulation Research Unit (013242510), Emergency medicine/Medicine/Surgery (013240200)
id
3522db93-76f1-47af-af7a-ba3b43b05f2e (old id 1113649)
alternative location
http://ltarkiv.lakartidningen.se/artNo16891
date added to LUP
2016-04-01 17:13:45
date last changed
2022-03-23 00:11:25
@article{3522db93-76f1-47af-af7a-ba3b43b05f2e,
  abstract     = {{HIV disease progression and the effect of replacement therapy with clotting factor concentrates (CFCs) were studied in 100 Swedish haemophiliacs, mean age at seroconversion 29 years (range, 4-72). On average 16 years after seroconversion, 67 per cent of the patients had CD4+ cell counts of &lt; 200 x 10(6)/l, 50 per cent had developed AIDS, and 58 per cent had died. HIV disease progression was significantly slower in those aged less than 28 (median age) at seroconversion (P = 0.004). Moreover, mortality was inversely correlated to total annual CFC consumption after adjustment for age and HIV-related therapy, i.e., Pneumocystis carinii prophylaxis and antiretroviral drugs (P = 0.014), but unrelated to the purity of the CFCs used. After adjustment for age, annual CFC consumption and HIV-therapy, prophylactic replacement therapy was not associated with significantly better survival than on-demand treatment. It is concluded that in HIV-positive haemophiliacs replacement therapy may have a beneficial effect on the immune system, and that CFC purity and the regimen (prophylaxis vs on-demand) would seem to be factors of minor importance.}},
  author       = {{Astermark, Jan and Berntorp, Erik and Stigendal, Lennart and Johnsson, Hans}},
  issn         = {{0023-7205}},
  keywords     = {{HIV-positivitet; Blödarsjuka; Hemofili B; Blodburen smitta; Faktor VIII; Faktor IX; Åldersfaktorer; Aids; AIDS-relaterade opportunistiska infektioner}},
  language     = {{swe}},
  number       = {{1}},
  pages        = {{48--50}},
  publisher    = {{Swedish Medical Association}},
  series       = {{Läkartidningen}},
  title        = {{Blödarsjuka med HIV. Långsammare infektionsförlopp hos yngre och vid större förbrukning av faktorkoncentrat}},
  url          = {{http://ltarkiv.lakartidningen.se/artNo16891}},
  volume       = {{95}},
  year         = {{1998}},
}